Thiazide diuretics to lower blood pressure in people on peritoneal dialysis
Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients
This trial will try a daily 25 mg hydrochlorothiazide pill to lower blood pressure in people on peritoneal dialysis whose blood pressure is above 140/90.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT07271420 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-center treatment-withdrawal crossover trial enrolling 10 chronic peritoneal dialysis patients with uncontrolled hypertension. Participants receive hydrochlorothiazide 25 mg once daily in addition to their usual care for 90 days, followed by a 14-day washout and a 90-day control period. Blood pressure changes (systolic and diastolic) are tracked to compare the on-treatment and off-treatment periods. The study excludes patients with very limited life expectancy or those planning conversion to hemodialysis or kidney transplant within three months.
Who should consider this trial
Good fit: Adults on chronic peritoneal dialysis with uncontrolled hypertension (SBP >140 mmHg and/or DBP >90 mmHg) who can attend the Hong Kong study site and are not scheduled for dialysis change or transplant within three months.
Not a fit: Patients without meaningful residual renal function, those with life expectancy under three months, or those planning to switch to hemodialysis or undergo transplantation soon are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, adding hydrochlorothiazide could improve blood pressure control and potentially reduce cardiovascular risk in peritoneal dialysis patients with some residual kidney function.
How similar studies have performed: Prior data are limited and mixed; small studies and clinical experience suggest thiazides can lower blood pressure when residual renal function exists, but robust evidence in peritoneal dialysis patients is sparse.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg) Exclusion Criteria: * Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months
Where this trial is running
Hong Kong
- Prince of Wales Hospital. The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Gordon Chan, MD, MRCP
- Email: cck295@ha.org.hk
- Phone: 0085235052211
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.